Search Results
Möller, H-J.: From Kraepelin to DSM-V: The concept of schizophrenia. Nemzetközi Szkizofrénia Szimpózium kivonata. Budapest, 2006. Murray, R. M., Dutta, R.: The right answer for the wrong reasons
Tandon, R., Nasrallah, H. A., Keshavan, M. S.: Schizophrenia, “just the facts” 5. Treatment and prevention. Past, present, and future. Schizophr. Res., 2010, 122 , 1
Seshadri, S., Kamiya, A., Yokota, Y. és mtsai: Disrupted-in-Schizophrenia-1 expression is regulated by beta-site amyloid precursor protein cleaving enzyme-1-neuregulin cascade. Proc. Natl. Acad. Sci. USA, 2010, 107 , 5622
Van Os, J., Kapur, S.: Schizophrenia. Lancet, 2009, 374 , 635–645. Kapur S. Schizophrenia Lancet 2009
BH, Kim JH, Oh S, et al. Clinical features of parricide in patients with schizophrenia. Aust N Z J Psychology 2012; 46: 621–629. 12 Klein CA, Hirachan S. The masks of
4394 Rubin, L. H., Carter, C. S., Drogos, L., et al.: Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr. Res., 2010, 124 , 13
Conley, R. R., Kelly, D. L.: Second-generation antipsychotics for schizophrenia: a review of clinical pharmacology and medication-associated side effects. Isr. J. Psychiatry Relat. Sci., 2005, 42 , 51
cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia. Brain Stimulat. 2012; 5: 337–346. 33 Rostami R, Kazemi R, Nitsche MA
therapeutic agents for schizophrenia. Recent Patents CNS Drug Discover. 1, 43–53 (2006) Hashimoto K. Glycine transporter inhibitors as therapeutic agents for schizophrenia
seizures, stroke, and schizophrenia also lacks proof. The arguments on an immune-mediated illness are not strong enough either. A more likely cause could be an infectious disease, such as malaria, meningitis, or encephalitis, which might be exaggerated by
